The BBC3 Knockout DLD-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human DLD-1 colorectal adenocarcinoma cell line. This product provides a heterogeneous pool of cells harboring targeted disruption of the BBC3 gene, which encodes the pro-apoptotic BH3-only protein PUMA. The polyclonal format offers a robust loss-of-function model suitable for studying apoptotic signaling without clonal selection artifacts. The cells are delivered as a ready-to-use polyclonal population, enabling immediate experimental application in cancer biology and drug discovery.
The DLD-1 host cell line originates from a Dukes?? type C colorectal adenocarcinoma and is widely employed as a model system for colorectal cancer research. DLD-1 cells harbor well-characterized mutations in APC, KRAS, and TP53 (p53 S241F), rendering them tumorigenic and reflective of key oncogenic pathways. These genetic alterations disrupt cell cycle control, Wnt signaling, and apoptosis regulation, making the line particularly valuable for investigating the interplay between oncogenic drivers and cell death mechanisms. The epithelial morphology and stable growth characteristics further facilitate reproducible in vitro assays.
BBC3 (PUMA) functions as a pivotal mediator of apoptosis, acting downstream of transcriptional regulators such as TP53, FOXO3a, E2F1, and p73. Upon cellular stress, including DNA damage, hypoxia, or growth factor withdrawal, BBC3 is upregulated and translocates to the mitochondria, where it binds and neutralizes anti-apoptotic BCL-2 family members including BCL2, BCL2L1 (BCL-XL), and MCL1. This interaction liberates BAX and BAK, enabling their oligomerization and mitochondrial outer membrane permeabilization (MOMP). MOMP facilitates the release of cytochrome c (CYCS) into the cytosol, promoting APAF1-mediated activation of caspase-9 and subsequent cleavage of effector caspase-3, thereby executing the apoptotic program.
In the context of DLD-1 cells, which express a mutant p53 (S241F) with compromised transcriptional activity, the BBC3 knockout model allows dissection of p53-dependent and p53-independent apoptotic pathways. Aberrant apoptosis regulation is a hallmark of colorectal cancer, and disruption of BBC3 may influence sensitivity to chemotherapeutic agents and targeted therapies. By eliminating PUMA expression, researchers can investigate compensatory survival mechanisms, alterations in BCL-2 family interactions, and shifts in mitochondrial priming. This model is particularly relevant for studying resistance to DNA-damaging agents and for evaluating strategies to restore apoptotic signaling in tumors with defective p53.
This polyclonal BBC3 knockout pool is suited for a wide range of applications, including apoptosis assays such as Annexin V/PI staining and TUNEL, mitochondrial membrane potential measurements with JC-1, and cytochrome c release analyses. Western blotting and RT-qPCR can be employed to confirm PUMA ablation and assess downstream caspase cleavage (caspase-9, caspase-3). Co-immunoprecipitation studies enable mapping of BCL-2 family interactomes, while cell viability assays (MTT, CellTiter-Glo) quantify drug responses. Additionally, ChIP-qPCR and luciferase reporter assays can probe p53 transcriptional activity at the BBC3 promoter. For further details or technical support, please contact Ascent Research.
